Pegaspargase: Two Pediatric Case Studies of Delayed Urticaria Preceding Anaphylactic Reactions Postadministration.

Clinical Journal of Oncology Nursing
Kathleen R Busack

Abstract

Pegaspargase, a chemotherapy drug known to improve survival outcomes in acute lymphoblastic leukemia, is associated with a risk for hypersensitivity reactions. At a children's hospital in the midwestern United States, two patients developed unusual reactions consisting of disseminated urticaria about two weeks after their second dose of pegaspargase. Both patients then proceeded to have severe anaphylaxis with the third dose of pegaspargase. These cases highlight the importance of advanced practice nurses being alert for the occurrence of unusual and delayed reactions to chemotherapy administration.

References

Jan 1, 1980·Medical and Pediatric Oncology·R J SpiegelD G Poplack
Oct 25, 2011·Pediatric Blood & Cancer·Mahati Pidaparti, Bruce Bostrom
Nov 25, 2014·Pediatric Blood & Cancer·Louise Tram HenriksenUNKNOWN Nordic Society of Paediatric Haematology and Oncology (NOPHO) group
Jul 5, 2016·Pediatric Blood & Cancer·Robin Q H KloosInge M van der Sluis
Jun 13, 2017·Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses·Deborah WoodsEmily Browne
Nov 23, 2017·Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses·Emily K BrowneBelinda N Mandrell
Apr 29, 2019·Drugs·Young-A HeoSusan J Keam
May 18, 2019·Leukemia & Lymphoma·Bernard L MariniAnthony J Perissinotti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Anaphylaxis

Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death.